IgA and IgG Subclass Deficiencies Workup

  • Author: Terry W Chin, MD, PhD; Chief Editor: Harumi Jyonouchi, MD   more...
 
Updated: Sep 28, 2010
 

Laboratory Studies

  • Because B cells produce circulating levels of immunoglobulin (Ig)G, IgA, and IgM, any or any combination of them may be low depending on the stage of B-cell maturation that is affected. In addition, all or any combination of the IgG subclasses IgG1, IgG2, IgG3, or IgG4 may be low. Physicians must compare the patient's specific levels to age-appropriate control data.
  • In 1971, the World Health Organization first defined selective IgA deficiency as a serum IgA level of less than 5 mg/dL, with normal levels of IgG and IgM and intact T-lymphocyte function.
    • An international consensus panel defined primary IgA deficiency as a serum IgA level of less than 7 mg/dL (< 0.07 g/L) in any patient older than 4 years. Therefore, IgA deficiency is an IgA level of less than 5-7 mg/dL. Other causes of hypogammaglobulinemia must be excluded. Patients with primary IgA deficiency also have a normal IgG antibody response to vaccination.
    • The gradual increase in production of IgA with aging makes a comparison with age-appropriate values necessary. Therefore, awareness of whether the local laboratory uses age-matched control values is important.
    • Similarly, whether the IgA measurement is based on nephelometry is important because levels less than 10 mg/dL are not reliable using this method.[22] The Mayo Clinic can accurately determine levels less than 2 mg/dL. IBT Laboratories can accurately measure values down to 7 mg/dL.
    • The international consensus panel has stated, "a male or female patient greater than 4 years of age who has a serum IgA at least 2 standard deviations below normal for age but normal serum IgG and IgM and in whom other causes of hypogammaglobulinemia have been excluded" has probable primary IgA deficiency.
  • Partial IgA deficiency is defined as a serum IgA level less than that expected for the patient's age (ie, < 2 standard deviations from the mean).[22] This finding is most common in children because of development of their IgA-specific B-cell system is delayed. When followed up serially, serum IgA levels increase in about half of these patients, increasing toward normal values by the time children are aged 5 years. However, individuals whose IgA level is less than 5 mg/dL usually do not have this transient IgA deficiency.
  • A diagnosis of primary IgA deficiency requires the ability to have a normal IgG antibody response to vaccination with childhood vaccines, such as those for diphtheria, pertussis, varicella, hepatitis B, and H influenzae. Therefore, a patient who has or who develops an impaired antibody response may also develop combined IgG subclass deficiency or common variable immunodeficiency (CVID).
    • Prevaccination and postvaccination serum antibody titers are ideally tested simultaneously and compared to enhance the reliability of the results. However, children younger than 2 years do not respond well to polysaccharide vaccines.
    • The new consensus statement implies that a diagnosis of primary IgA deficiency requires the ability to have a normal IgG antibody response to vaccination. A patient who develops an impaired antibody response possibly may have developed CVID or combined IgG subclass deficiency.
  • Further laboratory studies can clarify the association of B-cell deficiency with other disorders (see History). Identifying concomitant allergy in patients with chronic respiratory infections may require in vivo or in vitro allergy testing and management.
    • As many as one half of patients with selective IgA deficiency have milk precipitins (precipitable IgG antibody against cow's milk), and they may have symptoms suggesting a milk protein allergy. Circulating immune complexes are also described in these individuals. Most of these patients do not have symptoms that can be attributed to the presence of these antibodies.
    • The need to obtain other studies often depends on the diseases (if any) associated with B-cell deficiency.
  • Some patients may have a concurrent IgG subclass deficiency and may not respond well to polysaccharide antigens. Determining their specific antibody levels to antigens from pneumococcal, meningococcal, or H influenzae bacteria may help distinguish antigen-specific antibody deficiency (ASAD) or specific antibody deficiency (SAD) because these patients are more prone to develop recurrent infections and serious sequelae such as bronchiectasis. Measurements of the response to pneumococcal polysaccharides is preferred,[24] although others prefer antibody response to meningococcal vaccination.[25] The response to bacterial polysaccharide antigens depends on the age of the patient and the immunogenicity of the different bacterial serotypes.
    • Patients suspected of antigen-specific antibody deficiency have normal antibodies-to–protein antigens. They also have normal or near normal serum Ig levels, excluding CVID.
    • This syndrome rarely is diagnosed in children younger than 2 years because children who are approximately that age usually do not respond to most vaccine-derived polysaccharide antigens.
    • Some physicians recommend measuring preexisting pneumonococcal antibodies first and then checking the results before giving the polysaccharide vaccine. High preimmunization antibodies have been associated with local and systemic reactions (usually fever), which should be treated with appropriate medications.
  • Some controversy surrounds the laboratory definition of ASAD and SAD. Any acceptable definition of a normal response to immunization must account for age-related differences in the serotype-specific antibody concentration and in the number of serotypes inducing an arbitrarily defined adequate response. The definition should depend on familiarity with the clinical laboratory performing these types of tests. Serotypes 6A, 9N, 14, and 23F have low immunogenicity.
    • Some suggest that absence of response means that the patient had no response to all of the pneumococcal serotypes tested. A low or partial response is an adequate response to 50% of the serotypes tested in a child aged 2-5 years and to more than 70% in a child older than 6 years. Data supports that a response of 50% or higher following the 23-valent pneumococcal vaccine is normal.[26]
    • Others suggested that SAD be diagnosed by the absent of a response in two assays, one using the 23-valent pneumococcal vaccine as a screening test and the definitive measurement of specific serotypes such as 14, 19F and 23F.[12]
    • Some measured the response to 5 serotypes, defining SAD as those with an inadequate response to at least 4 (3, 4, 9N, 18C, and 19F).[11] Others define SAD as those with fewer than 9 of 12 responses to vaccination with polyvalent pneumococcal vaccine.[17]
    • Protective effect of pneumococcal strains is observed with antibody concentrations of greater than 300 ng (or >2 mcg/mL).
  • To identify an IgA deficiency caused by drugs, administer a substitute drug for 3-6 months before retesting the serum IgA level.
Next

Imaging Studies

  • No particular radiologic finding is specific for the B-cell deficiency syndromes described in this article. However, bronchiectasis appears to be associated with IgG subclass deficiency or specific polysaccharide antibody production deficiency.[15]
  • In addition, patients with cystic fibrosis was reported to have low IgG2 at high frequency as much as 29%.[27] Therefore, these patients' pulmonary status should be periodically evaluated with a high-resolution CT to determine the presence of bronchiectasis.
  • The development of pulmonary sequelae appears to be 5 times more frequent in IgG subclass deficiencies than in selective IgA deficiency.[28]
Previous
Next

Other Tests

  • Chronic sinusitis can be a therapeutic challenge because therapy with antibiotics, N -acetylcysteine, and topical intranasal beclomethasone fails to clear pathogens and does not decrease sinus inflammation. Documentation with sinus CT may be helpful.
  • Patients with chronic diarrhea and malabsorption may have blunting of the villi, as seen on jejunal biopsy specimens. In patients with selective IgA deficiency, IgM-secreting plasma cells are observed in the lamina propria instead of IgA plasma cells. However, the overall lymph node architecture is normal in selective IgA deficiency.
  • Pulmonary function testing may show an obstruction pattern in certain patients with hypogammaglobulinemia, indicating asthma. The prevention of permanent lung damage should be a major goal of medical management. Therefore, periodic measurements of their pulmonary status may be helpful to monitor a major source of morbidity in these patients.
  • The incidence of hyperactivity may also be increased.
Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Terry W Chin, MD, PhD  Associate Director, Pediatric Allergy/Immunology/Pulmonology, Miller Children's Hospital, Long Beach Memorial Medical Center; Associate Professor, Department of Pediatrics, University of California, Irvine, School of Medicine

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Thoracic Society, California Thoracic Society, Clinical Immunology Society, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Ann O'Neill Shigeoka, MD †  Former Clinical Associate Professor, Department of Pediatrics, Division of Immunology-Rheumatology, University of Utah School of Medicine

Ann O'Neill Shigeoka, MD † is a member of the following medical societies: American Federation for Medical Research, Clinical Immunology Society, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

John Wilson Georgitis, MD  Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD  Associate Professor, Division of Pulmonary Allergy/Immunology and Infectious Diseases, Department of Pediatrics, UMDNJ-New Jersey Medical School

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Mucosal Immunology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Plebani A, Ugazio AG, Meini A, et al. Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant?. Clin Immunol Immunopathol. Jul 1993;68(1):46-50. [Medline].

  2. Santaella ML, Peredo R, Disdier OM. IgA deficiency: clinical correlates with IgG subclass and mannan-binding lectin deficiencies. P R Health Sci J. Jun 2005;24(2):107-10. [Medline].

  3. Anantaphruti MT, Nuamtanong S, Dekumyoy P. Diagnostic values of IgG4 in human gnathostomiasis. Trop Med Int Health. Oct 2005;10(10):1013-21. [Medline].

  4. Constantin C, Huber WD, Granditsch G, et al. Different profiles of wheat antigens are recognised by patients suffering from coeliac disease and IgE-mediated food allergy. Int Arch Allergy Immunol. Nov 2005;138(3):257-66. [Medline].

  5. Litzman J, Sevcikova I, Stikarovska D, et al. IgA deficiency in Czech healthy individuals and selected patient groups. Int Arch Allergy Immunol. Oct 2000;123(2):177-80. [Medline].

  6. Weber-Mzell D, Kotanko P, Hauer AC, et al. Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur J Clin Invest. Mar 2004;34(3):224-8. [Medline].

  7. Aghamohammadi A, Cheraghi T, Gharagozlou M, et al. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. Jan 2009;29(1):130-6. [Medline].

  8. Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol. 2008;147(2):87-92. [Medline].

  9. Slyper AH, Pietryga D. Conversion of selective IgA deficiency to common variable immunodeficiency in an adolescent female with 18q deletion syndrome. Eur J Pediatr. Feb 1997;156(2):155-6. [Medline].

  10. Cunningham-Rundles C, Brandeis WE, Pudifin DJ, et al. Autoimmunity in selective IgA deficiency: relationship to anti-bovine protein antibodies, circulating immune complexes and clinical disease. Clin Exp Immunol. Aug 1981;45(2):299-304. [Medline].

  11. Jeurissen A, Moens L, Raes M, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens. Clin Chem. Mar 2007;53(3):505-10. [Medline].

  12. Tuerlinckx D, Vermeulen F, Pekus V, et al. Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies. Clin Exp Immunol. Aug 2007;149(2):295-302. [Medline].

  13. Boyle RJ, Le C, Balloch A, et al. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. Dec 2006;146(3):486-92. [Medline].

  14. van Kessel DA, van Velzen-Blad H, van den Bosch JM, et al. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J. Mar 2005;25(3):482-9. [Medline].

  15. Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. Jan 2005;127(1):197-204. [Medline].

  16. Wiertsema SP, Veenhoven RH, Sanders EA, et al. Immunologic screening of children with recurrent otitis media. Curr Allergy Asthma Rep. Jul 2005;5(4):302-7. [Medline].

  17. Cheng YK, Decker PA, O'Byrne MM, et al. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol. Sep 2006;97(3):306-11. [Medline].

  18. Costa Carvalho BT, Nagao AT, Arslanian C, et al. Immunological evaluation of allergic respiratory children with recurrent sinusitis. Pediatr Allergy Immunol. Sep 2005;16(6):534-8. [Medline].

  19. Mrabet-Dahbi S, Breuer K, Klotz M, et al. Deficiency in immunoglobulin G2 antibodies against staphylococcal enterotoxin C1 defines a subgroup of patients with atopic dermatitis. Clin Exp Allergy. Mar 2005;35(3):274-81. [Medline].

  20. Gregorek H, Dzierzanowska-Fangrat K, Woynarowski M, et al. Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-alpha therapy: correlation with specific IgG subclass responses to HBsAg. J Hepatol. Apr 2005;42(4):486-90. [Medline].

  21. de Laat PC, Weemaes CM, Bakkeren JA, et al. Familial selective IgA deficiency with circulating anti-IgA antibodies: a distinct group of patients?. Clin Immunol Immunopathol. Jan 1991;58(1):92-101. [Medline].

  22. Schaffer FM. Clinical assessment and management of abnormal IgA levels. Ann Allergy Asthma Immunol. Mar 2008;100(3):280-2. [Medline].

  23. Toptygina AP, Pukhalsky AL, Alioshkin VA. Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history. Clin Diagn Lab Immunol. Jul 2005;12(7):845-7. [Medline].

  24. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. Nov 2007;99(5):462-4. [Medline].

  25. Rezaei N, Aghamohammadi A, Siadat SD, et al. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies. Vaccine. Jul 20 2007;25(29):5308-14. [Medline].

  26. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, et al. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol. Dec 2006;118(6):1336-41. [Medline].

  27. Garside JP, Kerrin DP, Brownlee KG, et al. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr Pulmonol. Feb 2005;39(2):135-40. [Medline].

  28. Ozkan H, Atlihan F, Genel F, et al. IgA and/or IgG subclass deficiency in children with recurrent respiratory infections and its relationship with chronic pulmonary damage. J Investig Allergol Clin Immunol. 2005;15(1):69-74. [Medline].

  29. Kutukculer N, Karaca NE, Demircioglu O, et al. Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol. Mar 2007;18(2):167-73. [Medline].

  30. Cohn JA, Skorpinski E, Cohn JR. Prevention of pneumococcal infection in a patient with normal immunoglobulin levels but impaired polysaccharide antibody production. Ann Allergy Asthma Immunol. Nov 2006;97(5):603-5. [Medline].

  31. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. Aug 1998;17(8):685-91. [Medline].

  32. Meyts I, Bossuyt X, Proesmans M, et al. Isolated IgG3 deficiency in children: to treat or not to treat? Case presentation and review of the literature. Pediatr Allergy Immunol. Nov 2006;17(7):544-50. [Medline].

  33. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. Nov 2008;28(4):833-49, ix. [Medline].

  34. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. Nov 2008;28(4):765-78, viii. [Medline].

  35. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. Nov 2005;25(11 Pt 2):78S-84S. [Medline].

  36. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. Aug 15 2005;62(16 Suppl 3):S5-11. [Medline].

  37. Sorensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. Aug 1998;102(2):215-21. [Medline].

  38. Lawton AR. IgG subclass deficiency and the day-care generation. Pediatr Infect Dis J. May 1999;18(5):462-6. [Medline].

  39. Wolpert J, Knutsen AP. Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol. 1998;12:183-91.

  40. al-Attas RA, Rahi AH. Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. J Clin Immunol. Sep 1998;18(5):368-71. [Medline].

  41. Buehring I, Friedrich B, Schaaf J, et al. Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Clin Exp Immunol. Sep 1997;109(3):468-72. [Medline].

  42. Farhoudi A, Aghamohammadi A, Moin M, et al. Distribution of primary immunodeficiency disorders diagnosed in the Children's Medical Center in Iran. J Investig Allergol Clin Immunol. 2005;15(3):177-82. [Medline].

  43. Feydy A, Sibilia J, De Kerviler E, et al. Chest high resolution CT in adults with primary humoral immunodeficiency. Br J Radiol. Dec 1996;69(828):1108-16. [Medline].

  44. Gogorcena MA, Castillo M, Casajuana J, et al. Accessibility to primary health care centers: experience and evaluation of an appointment system program. Qual Assur Health Care. Mar 1992;4(1):33-41. [Medline].

  45. Kainulainen L, Nikoskelainen J, Vuorinen T, et al. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med. Apr 1999;159(4 Pt 1):1199-204. [Medline].

  46. Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. Nov 1999;104(5):1031-6. [Medline].

  47. Kavanaugh AF, Huston DP. Variable expression of IgG2 deficiency. J Allergy Clin Immunol. Jul 1990;86(1):4-10. [Medline].

  48. Kuijpers TW, Weening RS, Out TA. IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens. Allergol Immunopathol (Madr). Jan-Feb 1992;20(1):28-34. [Medline].

  49. Mila J, Matamoros N, Pons de Ves J, et al. [The Spanish Registry of Primary Immunodeficiencies. REDIP-1998]. Sangre (Barc). Apr 1999;44(2):163-7. [Medline].

  50. Papadopoulou A, Mermiri D, Taousani S, et al. Bronchial hyper-responsiveness in selective IgA deficiency. Pediatr Allergy Immunol. Sep 2005;16(6):495-500. [Medline].

  51. Schaffer FM, Palermos J, Zhu ZB, et al. Individuals with IgA deficiency and common variable immunodeficiency share polymorphisms of major histocompatibility complex class III genes. Proc Natl Acad Sci U S A. Oct 1989;86(20):8015-9. [Medline].

  52. Shackelford PG. IgG subclasses: importance in pediatric practice. Pediatr Rev. Aug 1993;14(8):291-6. [Medline].

  53. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child. Jun 1996;74(6):527-30. [Medline].

  54. Soderstrom T, Soderstrom R, Enskog A. Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency. Cancer. Sep 15 1991;68(6 Suppl):1426-9. [Medline].

  55. Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. Jun 1998;101(6 Pt 1):848-9. [Medline].

  56. Wilton AN, Cobain TJ, Dawkins RL. Family studies of IgA deficiency. Immunogenetics. 1985;21(4):333-42. [Medline].

 
Previous
Next
 
Table. Immune Globulin, Intravenous[33, 34, 35, 36]
Brand(Manufacturer)Manufacturing ProcesspHAdditives (IVIg products containing sucrose are most often associated with renal dysfunction, acute renal failure, and osmotic nephrosis, particularly with preexisting risk factors [eg, history of renal insufficiency, diabetes mellitus, age >65 y, dehydration, sepsis, paraproteinemia, nephrotoxic drugs]) Parenteral Form and Final ConcentrationsIgA Content mcg/mL
Carimune NF



(CSL Behring)



Kistler-Nitschmann fractionation; pH 4, nanofiltration6.4-6.86% solution: 10% sucrose, < 20 mg NaCl/g proteinLyophilized powder 3%, 6%, 9%, 12%Trace
Flebogamma



(Grifols USA)



Cohn-Oncley fractionation, PEG precipitation, ion-exchange chromatography, pasteurization5.1-6Sucrose free, contains 5% D-sorbitolLiquid 5%< 50
Gammagard Liquid 10%



(Baxter Bioscience)



Cohn-Oncley cold ethanol fractionation, cation and anion exchange chromatography, solvent detergent treated, nanofiltration, low pH incubation 4.6-5.10.25M glycineReady-for-use Liquid 10%37
Gamunex



(Talecris Biotherapeutics)



Cohn-Oncley fractionation, caprylate-chromatography purification, cloth and depth filtration, low pH incubation4-4.5Does not catain carbohydrate stabilizers (eg, sucrose, maltose), contains glycineLiquid 10%46
Gammaplex



(Bio Products)



Solvent/detergent treatment targeted to enveloped viruses; virus filtration using Pall Ultipor to remove small viruses including nonenveloped viruses; low pH incubation 4.8-5.1Contains sorbitol (40 mg/mL); do not administer if fructose intolerantReady-for-use solution 5%< 10
Iveegam EN



(Baxter Bioscience)



Cohn-Oncley fraction II/III; ultrafiltration; pasteurization6.4-7.25% solution: 5% glucose, 0.3% NaClLyophilized powder 5%< 10
Polygam S/D



Gammagard S/D



(Baxter Bioscience for the American Red Cross)



Cohn-Oncley cold ethanol fractionation, followed by ultracentrafiltration and ion exchange chromatography; solvent detergent treated 6.4-7.25% solution: 0.3% albumin, 2.25% glycine, 2% glucoseLyophilized powder 5%, 10%< 1.6 (5% solution)
Octagam



(Octapharma USA)



9/24/10: Withdrawn from market because of unexplained reports of thromboembolic events



Cohn-Oncley fraction II/III; ultrafiltration; low pH incubation; S/D treatment pasteurization5.1-610% maltoseLiquid 5%200
Panglobulin



(Swiss Red Cross for the American Red Cross)



Kistler-Nitschmann fractionation; pH 4 incubation, trace pepsin, nanofiltration6.6Per gram of IgG: 1.67 g sucrose, < 20 mg NaClLyophilized powder 3%, 6%, 9%, 12%720
Privigen Liquid 10%



(CSL Behring)



Cold ethanol fractionation, octanoic acid fractionation, and anion exchange chromatography; pH 4 incubation and depth filtration4.6-5L-proline (approximately 250 mmol/L) as stabilizer; trace sodium; does not contain carbohydrate stabilizers (eg, sucrose, maltose) Ready-for use liquid 10%< 25
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.